Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2009; 19(02): 155-157
DOI: 10.4103/0971-3026.50839
Musculosksletal

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case

Gyan Chand
Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi-110 002, India
,
Veena Chowdhury
Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi-110 002, India
,
A Manchanda
Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi-110 002, India
,
Sapna Singh
Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi-110 002, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Arthropathy is a well known side effect of the iron chelator deferiprone (L1); however, the imaging findings in deferiprone-induced arthropathy are not well known. In this article, we describe the typical radiographic and MRI findings in a patient receiving regular blood transfusions who developed arthropathy after long-term therapy with the oral iron chelator deferiprone (L1). Deferiprone primarily affects the articular cartilage and the changes include synovial thickening, articular cartilage thickening, and subchondral bone erosions.

Keywords

Arthropathy - deferiprone - magnetic resonance imaging


Publication History

Article published online:
31 July 2021

© 2009. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Diav-Citrin O, Koren G. Oral iron chelation with deferiprone. Pediatr Clin North Am 1997;44:235-47.
  • 2 Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator: A multicenter study. Br J Haematol 2000;108:305-12.
  • 3 Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, et al . Arthropathy in thalassemia patients receiving deferiprone. Lancet 1994;343:1471-2.
  • 4 Agarwal MB, Gupta SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, et al . Long term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-6.
  • 5 Agarwal MB. Oal iron chelation: A review with special emphasis on Indian work on deferiprone. Indian J Pediatr 1993;60:509-16.
  • 6 Kellenberger JC, Schmugge M, Saurenmann T. Radiographic and MRI features of deferiprone related arthtropathy of the knees in patients with β- thalassaemia. AJR Am J Roentgenol 2004;182:989-94.
  • 7 Chan Y, Li C, Chu WC, Pang L, Cheng JC, Chik KW. Deferoxamine induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR Imaging Appearance. AJR Am J Roentgenol 2000;175:1756-6.